CAPR May 2024 2.500 call
| Previous close | 2.8500 |
| Open | 2.8500 |
| Bid | 1.4500 |
| Ask | 4.0000 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 2.8500 - 2.8500 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
Simply Wall St.Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
GlobeNewswireCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting- -Company Granted Subsequent Type-B Clinical Meeting with FDA in Second Quarter to Continue to Discuss Pathway to BLA- -Capricor Management to Host Virtual Investor Webcast to Discuss Latest Program Updates on Monday, April 29 at
ZacksWall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
